Avidity Biosciences Inc’s recently made public that its Chief Commercial Officer Mosbrooker Eric unloaded Company’s shares for reported $5.76 million on Aug 06 ’25. In the deal valued at $44.06 per share,130,807 shares were sold. As a result of this transaction, Mosbrooker Eric now holds 55,000 shares worth roughly $2.52 million.
Then, WILSON TROY EDWARD sold 65,554 shares, generating $2,949,930 in total proceeds. Upon selling the shares at $45.00, the Director now owns 17,776 shares.
Before that, WILSON TROY EDWARD sold 29,500 shares. Avidity Biosciences Inc shares valued at $1,327,500 were divested by the Director at a price of $45.00 per share. As a result of the transaction, WILSON TROY EDWARD now holds 69,425 shares, worth roughly $3.18 million.
A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in late June with a ‘”an Outperform”‘ rating. Wolfe Research began covering RNA with “an Outperform” recommendation on June 17, 2025. Raymond James started covering the stock on June 11, 2025. It rated RNA as “a Strong buy”.
Price Performance Review of RNA
On Monday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -1.10% to $45.78. Over the last five days, the stock has gained 22.60%. Avidity Biosciences Inc shares have risen nearly 11.36% since the year began. Nevertheless, the stocks have risen 57.43% over the past one year. While a 52-week high of $56.00 was reached on 08/06/25, a 52-week low of $21.51 was recorded on 04/09/25.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 44.19, which if violated will result in even more drops to 42.59. On the upside, there is a resistance level at 46.69. A further resistance level may holdings at 47.59.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-07-15, dropping by 84374.0 shares to a total of 16.26 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 16.34 million shares. There was a decline of -0.52%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 13, 2025 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
